Abstract
Hereditary hemorrhagic telangiectasia (HHT) is characterized by vessel alterations such as dilatation of postcapillary venules and arterio-venous communications, which account for the major clinical manifestations of the disease. Two types of HHT have been characterized HHT-1 and HHT-2, respectively, depending the former on endoglin mutations and the latter on activin receptor-like kinase 1 (ALK-1) mutations. Both endoglin and ALK-1 bind to the transforming growth factor (TGF) superfamily which, physiologically, regulates the activities of endothelial cells and also those related to the extracellular matrix. In this review, the salient features of TGF-β will be outlined with special reference to its activity on the immune system and on tumorigenesis. Furthermore, the involvement of TGF-β in the pathogenesis of some gastrointestinal diseases will be discussed and, in particular, in the course of liver disease, Helicobacter pylori infection and inflammatory bowel disease. In the light of these data and of animal model of HHT, the potential risk of developing other diseases in HHT patients will be discussed.
Keywords: Activin receptor-like kinase 1, angiogenesis, endoglin, hereditary hemorrhagic telangiectasia, immunity, transforming, growth factor, tumorigenesis
Current Pharmaceutical Design
Title: Involvement of the Transforming Growth Factor β in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia
Volume: 12 Issue: 10
Author(s): E. Jirillo, L. Amati, P. Suppressa, D. Cirimele, E. Guastamacchia, V. Covelli, E. Tafaro and C. Sabba
Affiliation:
Keywords: Activin receptor-like kinase 1, angiogenesis, endoglin, hereditary hemorrhagic telangiectasia, immunity, transforming, growth factor, tumorigenesis
Abstract: Hereditary hemorrhagic telangiectasia (HHT) is characterized by vessel alterations such as dilatation of postcapillary venules and arterio-venous communications, which account for the major clinical manifestations of the disease. Two types of HHT have been characterized HHT-1 and HHT-2, respectively, depending the former on endoglin mutations and the latter on activin receptor-like kinase 1 (ALK-1) mutations. Both endoglin and ALK-1 bind to the transforming growth factor (TGF) superfamily which, physiologically, regulates the activities of endothelial cells and also those related to the extracellular matrix. In this review, the salient features of TGF-β will be outlined with special reference to its activity on the immune system and on tumorigenesis. Furthermore, the involvement of TGF-β in the pathogenesis of some gastrointestinal diseases will be discussed and, in particular, in the course of liver disease, Helicobacter pylori infection and inflammatory bowel disease. In the light of these data and of animal model of HHT, the potential risk of developing other diseases in HHT patients will be discussed.
Export Options
About this article
Cite this article as:
Jirillo E., Amati L., Suppressa P., Cirimele D., Guastamacchia E., Covelli V., Tafaro E. and Sabba C., Involvement of the Transforming Growth Factor β in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia, Current Pharmaceutical Design 2006; 12 (10) . https://dx.doi.org/10.2174/138161206776361228
DOI https://dx.doi.org/10.2174/138161206776361228 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>In-vitro</i> Comparative Study of Different Brands of Metoclopramide Hydrochloride Tablets Marketed in Saudi Arabia
Current Drug Therapy Exploring Single Nucleotide Polymorphisms in ITGAV for Gastric, Pancreatic and Liver Malignancies: An Approach Towards the Discovery of Biomarker
Combinatorial Chemistry & High Throughput Screening Molecular Mechanisms of Anti-Inflammatory Activity Mediated by Flavonoids
Current Medicinal Chemistry The 21st Century Form of Vitamin E - Tocotrienol
Current Pharmaceutical Design Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery Use of Grape Polyphenols for Promoting Human Health: A Review of Patents
Recent Patents on Food, Nutrition & Agriculture Gastrin-Releasing Peptide as a Molecular Target for Inflammatory Diseases: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Use of Heat Shock Protein 70
Recent Patents on DNA & Gene Sequences Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Gastroesophageal Reflux Disease (GERD): Current Agents and Future Perspective
Current Pharmaceutical Design Comprehensive Analysis of the mRNA-lncRNA Co-expression Profile and ceRNA Networks Patterns in Chronic Hepatitis B
Current Genomics ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design Perinatal Management of Fetal Tumors
Current Pediatric Reviews Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry Therapeutic Benefits of <i>Piper nigrum</i>: A Review
Current Bioactive Compounds MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Fighting Type-2 Diabetes: Present and Future Perspectives
Current Medicinal Chemistry New Insights on the Antitumoral Properties of Prodiginines
Current Medicinal Chemistry Genome Analysis of Food Grade Lactic Acid-Producing Bacteria: From Basics to Applications
Current Genomics